Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15897085 | 1.00 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL15897200 | 1.00 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL15896807 | 0.97 | TSHR (0.37) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL15896800 | 0.97 | TSHR (0.37) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL15896790 | 0.97 | TSHR (0.37) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| Bromide SCHEMBL187505 | 0.96 | TSHR (0.36) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| Bromide SCHEMBL186788 | 0.96 | TSHR (0.36) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL803779 | 0.89 | MMP8 (0.38) | NPC1SMN1; SMN2LMNATSHRCYP3A4 | |
| SCHEMBL803777 | 0.89 | MMP8 (0.38) | NPC1SMN1; SMN2LMNATSHRCYP3A4 | |
| SCHEMBL803862 | 0.89 | MMP8 (0.38) | NPC1SMN1; SMN2LMNATSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785655-B2 | Ionic liquid solvents | DUBLIN CITY UNIVERSITY (IE) | 2014-07-22 | — | — | US | disclosed |
| US-20120071661-A1 | Ionic Liquid Solvents | DUBLIN CITY UNIVERSITY (IE) | 2012-03-22 | — | — | US | disclosed |
| WO-2010097412-A1 | IONIC LIQUID SOLVENTS | DUBLIN CITY UNIVERSITY (IE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071661-A1 | Ionic Liquid Solvents | EBP, PAICS, HACD3 | NPC1 1252/4885RAB9A 4843/4885SMN1; SMN2 2787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.